Diabetes increases the mortality of patients with COVID-19: a meta-analysis
- PDF / 1,377,314 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 92 Downloads / 180 Views
REVIEW ARTICLE
Diabetes increases the mortality of patients with COVID‑19: a meta‑analysis Zeng‑hong Wu1 · Yun Tang2 · Qing Cheng3 Received: 23 April 2020 / Accepted: 6 May 2020 © Springer-Verlag Italia S.r.l., part of Springer Nature 2020
Abstract Aims Nowadays, the ongoing pandemic of COVID-19 caused by the novel coronavirus Syndrome-Coronavirus-2 (SARSCoV-2) is an emerging, rapidly evolving situation. Complications such as hypertension, diabetes, COPD, cardiovascular disease, and cerebrovascular disease are major risk factors for patients with COVID-19. Methods No meta-analysis has explored if or not diabetes related to mortality of patients with COVID-19. Therefore, this meta-analysis first aims to explore the possible clinical mortality between diabetes and COVID-19, analyze if diabetes patients infected with SARS-CoV-2 are exposed to the worst clinical prognostic risk, and to evaluate the reliability of the evidence. Results Our results showed a close relationship between diabetes and mortality of COVID-19, with a pooled OR of 1.75 (95% CI 1.31–2.36; P = 0.0002). The pooled data were calculated with the fixed effects model (FEM) as no heterogeneity appeared in the studies. Sensitivity analysis showed that after omitting any single study or converting a random effect model to FEM, the main results still held. Conclusions Our meta-analysis showed that diabetes increases the mortality of patients with COVID-19. These results indicated the disturbance of blood glucose in the COVID-19 patients. More importantly, this meta-analysis grades the reliability of evidence for further basic and clinical research into the diabetes dysfunction in COVID-19 patients. Keywords COVID-19 · SARS-CoV-2 · Diabetes · Meta-analysis Abbreviations SARS-CoV-2 Syndrome-Coronavirus-2 COV Coronaviruses (CoV) ACE2 Angiotensin converting enzyme 2
Managed by Antonio Secchi. * Qing Cheng [email protected] 1
Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
3
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Introduction Coronaviruses (CoVs) are enveloped viruses with a positive single-stranded RNA virus, which are widely distributed in humans and animals to cause respiratory infections in humans [1]. Nowadays, the ongoing pandemic of COVID-19 caused by the novel coronavirus Syndrome-Coronavirus-2 (SARS-CoV-2) is an emerging, rapidly evolving situation [2]. As of April 14, 2020, 1,924,626 cases and 119,625 deaths in total have been confirmed around the world, suggesting that the overall death rate of COVID-19 was 6.2%. Although SARS-CoV-2 and SARS-CoV share similarities in phylogeny and clinical trials, the new type of coronavirus seems to have a higher spread and lower mortality [3]. A study repo
Data Loading...
